Serial measurements of lymphocytes, D-dimer, LDH, and CRP do not improve the ability to predict COVID-19 adverse outcomes

Jorge Pulido-Arenas, Daniela Saa-González, Oscar M. Muñoz, Alejandra Cañas-Arboleda

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Objective: We evaluated the discriminatory ability of variations in lymphocyte, D-dimer, C-reactive protein (CRP), and lactate dehydrogenase (LDH) serum levels at 48 to 72 hours of hospitalization compared with baseline measurements to predict unfavorable clinical outcomes in patients with COVID-19. Methods: We analyzed diagnostic test results based on a retrospective cohort to determine the ability of variations (gradients or ratios) in patients’ lymphocyte, D-dimer, CRP, and LDH serum levels taken 48 to 72 hours after hospital admission to predict adverse outcomes such as death, mechanical ventilation, or intensive care unit (ICU) admission developing. Results: Among 810 patients (56.1% men, age 61.6 ± 16.2 years), 37.5% had at least one adverse outcome; 28.2% required ICU admission, 26.5% required mechanical ventilation, and 19.4% died during hospitalization. In comparing baseline measurements with measurements at 48 to 72 hours, D-dimer, lymphocyte delta, LDH, and CRP had similar discriminatory ability (area under the receiver operating characteristic curve [AUC] 0.57 vs. 0.56, 0.53 vs. 0.57, 0.64 vs. 0.66, and 0.62 vs. 0.65, respectively). Conclusions: Measuring serum risk markers upon hospital admission can be used to evaluate risk of adverse outcomes in hospitalized patients with COVID-19. Repeating these measurements at 48 to 72 hours does not improve discriminatory ability.

Original languageEnglish
JournalJournal of International Medical Research
Volume51
Issue number5
DOIs
StatePublished - May 2023

Keywords

  • COVID-19
  • Serum biomarker
  • adverse outcome
  • mortality
  • prediction
  • retrospective cohort

Fingerprint

Dive into the research topics of 'Serial measurements of lymphocytes, D-dimer, LDH, and CRP do not improve the ability to predict COVID-19 adverse outcomes'. Together they form a unique fingerprint.

Cite this